Randwick Precinct Cancer Roundtable: Nanomedicine [May 22nd 2018]

Date Published: 
19 April 2018
Target Sites: 
Medicine (select for all events)
Medicine Staff Website (select for events only)
Centre for Big Data Research in Health (CBDRH)
LOWY
Prince of Wales Clinical School
Single Molecule Science
SoMS
The Kirby Institute (Decoupled. Publishing not working any more.)
The National Centre for Cancer Survivorship (NCCS)
image - Screen Shot 2018 04 19 At 3.23.43 Pm
Event date: 
22 May 2018 - 12:30pm to 1:30pm
Location: 
Edmund Blacket Functions Room, Prince of Wales Hospital
Event Type: 
In Conversation
Event open to: 
All
Seats available: 
100
Cost: 
FREE
Contact for inquiries: 
tcrn@unsw.edu.au
Booking deadline: 
Further info url: 
http://www.tcrn.unsw.edu.au/randwick-precinct-cancer-roundtable-0
Body: 

Topic: Nanomedicine

Facilitator: Prof David Goldstein

Guest presenter: Dr Joshua McCarroll

Interactive discussion facilitated by Prof David Goldstein

Director, Translational Cancer Research Network (TCRN)

Prof David Goldstein is a medical oncologist, he has been involved in a variety of clinical research projects ranging from laboratory basic science to novel therapeutics trials to psychosocial aspects of Cancer care. He has been Principal Investigator (PI) of a number of NHMRC and Cancer Australia funded trials including both investigator initiated and as Australian PI for multinational studies.

Invited speaker - Dr Joshua McCarroll

Research Fellow, Children’s Cancer Institute of Australia (CCIA)

Dr McCarroll leads a research team at Children’s Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney. He is also a member of the Australian Centre for Nanomedicine, ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, UNSW Sydney. In 2007, he returned to Australia from post-doctoral studies in the US to work at Children’s Cancer Institute with Prof Maria Kavallaris. He is internationally recognized for his work in using non-viral lipid nanoparticles to deliver gene-silencing drugs to treat human disease. The quality of his work is recognized by fellowships from the Cancer Institute NSW and current funding from NHMRC, Cancer Australia and Cancer Council.

Topics for discussion:

1.What is nanomedicine?
2.Why is there a compelling case to develop nanomedicine rather than just small molecules?
3.Passive versus active tumour cell targeting
4.What applications does nanotechnology have in cancer?
5.Challenges for nanomedicines reaching the clinic
6.Future directions